The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2017:
- 38 negotiations are currently underway with 9 new files added since the last update of March 31, 2017:
- Cosentyx (secukinumab): Use to treat psoriatic arthritis
- Cosentyx (secukinumab): Used to treat ankylosing spondylitis
- Erelzi (etanercept): Used to treat ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis
- Lenvima (lenvatinib): Used to treat thyroid cancer
- Mozobil (plerixafor): Used to treat non-Hodgkin lymphoma and multiple myeloma
- Pheburane (sodium phenylbutyrate): Used to treat urea cycle disorders
- Ravicti (glycerol phenylbutyrate): Used to treat urea cycle disorders
- Uptravi (selexipag): Used to treat pulmonary arterial hypertension
- XigDuo (dapagliflozin/metformin hydrochloride): Used to treat type 2 diabetes mellitus
- 149 joint negotiations have been completed with 1 file successfully negotiated since the last update of March 31, 2017:
- Jadenu (deferasirox): Used to treat chronic iron overload
- 50 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of March 31, 2017.
- 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of March 31, 2017.
For more information, please consult the pCPA’s website.